Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Oct;81(10):1420-1427.
doi: 10.1136/annrheumdis-2022-222435. Epub 2022 Jun 20.

Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial

Noemie Jourde-Chiche  1   2 , Nathalie Costedoat-Chalumeau  3   4 , Karine Baumstarck  5 , Anderson Loundou  5 , Laurence Bouillet  6 , Stéphane Burtey  2   7 , Valérie Caudwell  8 , Laurent Chiche  9 , Lionel Couzi  10 , Laurent Daniel  2   11 , Christophe Deligny  12 , Bertrand Dussol  7   13 , Stanislas Faguer  14 , Pierre Gobert  15 , Guillaume Gondran  16 , Antoine Huart  14 , Aurélie Hummel  17 , Emilie Kalbacher  18 , Adexandre Karras  19   20 , Marc Lambert  21 , Véronique Le Guern  22 , Ludivine Lebourg  23 , Sandrine Loubière  24 , Hélène Maillard-Lefebvre  25 , François Maurier  26 , Micheline Pha  27 , Viviane Queyrel  28 , Philippe Remy  29 , Françoise Sarrot-Reynauld  30 , David Verhelst  15 , Eric Hachulla  31 , Zahir Amoura  32 , Eric Daugas  33   34 ; WIN-Lupus study group
Affiliations
Randomized Controlled Trial

Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial

Noemie Jourde-Chiche et al. Ann Rheum Dis. 2022 Oct.

Abstract

Objectives: Lupus nephritis (LN) is a frequent complication of systemic lupus erythematosus (SLE). Severe (proliferative) forms of LN are treated with induction immunosuppressive therapy (IST), followed by maintenance IST, to target remission and avoid relapses. The optimal duration of maintenance IST is unknown. The WIN-Lupus trial tested whether IST discontinuation after 2‒3 years was non-inferior to IST continuation for two more years in proliferative LN.

Methods: WIN-Lupus was an investigator-initiated multicentre randomised controlled trial. Patients receiving maintenance IST with azathioprine or mycophenolate mofetil for 2-3 years, and hydroxychloroquine, were randomised (1:1) into two groups: (1) IST continuation and (2) IST discontinuation. The primary endpoint was the relapse rate of proliferative LN at 24 months. Main secondary endpoints were the rate of severe SLE flares, survival without renal relapse or severe flare, adverse events.

Results: Between 2011 and 2016, 96 patients (out of 200 planned) were randomised in WIN-Lupus: IST continuation group (n=48), IST discontinuation group (n=48). Relapse of proliferative LN occurred in 5/40 (12.5%) patients with IST continuation and in 12/44 (27.3%) patients with IST discontinuation (difference 14.8% (95% CI -1.9 to 31.5)). Non-inferiority was not demonstrated for relapse rate; time to relapse did not differ between the groups. Severe SLE flares (renal or extrarenal) were less frequent in patients with IST continuation (5/40 vs 14/44 patients; p=0.035). Adverse events did not differ between the groups.

Conclusions: Non-inferiority of maintenance IST discontinuation after 2‒3 years was not demonstrated for renal relapse. IST discontinuation was associated with a higher risk of severe SLE flares.

Trial registration number: NCT01284725.

Keywords: Glucocorticoids; Hydroxychloroquine; Lupus Erythematosus, Systemic; Lupus Nephritis; Outcome Assessment, Health Care.

PubMed Disclaimer

Conflict of interest statement

Competing interests: NJ-C reports receiving non-financial support from Sanofi-Genzyme and Vifor; speaking and consulting fees from Vifor and Otsuka; research grant from Fresenius Medical Care; outside the submitted work. NC-C reports research grant from Roche; outside the submitted work. LB reports speaking fees from GSK, Novartis, Biocryst, Takeda, Behring and Blueprint; research grants from Takeda, GSK, Sanofi, Biocryst, Novartis; outside the submitted work. LCh reports speaking fees from BMS and non-financial support from AstraZeneca; outside the submitted work. LCo reports speaking fees from Astellas, Chiesi, Novartis, Sandoz, Otsuka, GSK, Biotest; consultancy fees from Biotest, Hansa, Novartis; research grants from Novartis, Astellas; travel funding from Astellas, Chiesi, Novartis, Sandoz, Vifor; outside the submitted work. LD reports speaking fees from AstraZeneca and Janssen. BD reports speaking fees from Genzyme and Novonordisk; consultancy fees from Amicus; research grant from Shire; outside the submitted work. SF reports speaking fees from Asahi, Vifor and Sanofi; consultancy fees from Abyonyx Pharma; outside the submitted work. GG reports speaking fees from Genzyme, Pfizer and Novartis; non-financial support from Novartis, Amgen, Addmedicca, Lilly, Abbvie, Amicus therapeutics, Shire, Pfizer and LFB medicaments; outside the submitted work. AH reports speaking fees from Janssen and Pfizer; outside the submitted work. AK reports speaking fees from Vifor, GSK, AstraZeneca, Roche; consultancy fees from Novartis, GSK, Bohringer-Ingelheim; non-financial support from Vifor, Sanofi and Alexion; outside the submitted work. ML reports speaking fees from Chugai-Roche, Bayer, Pfizer, Leopharma; grant from Chugai-Roche; outside the submitted work. VQ reports consultancy fees from Boehringer Ingelheim and GSK; outside the submitted work. EH reports consulting fees from Johnson&Johnson, Boehringer Ingelheim, Bayer, GSK, Roche-Chugai, Sanofi-Genzyme; speaking fees from Johnson&Johnson, GSK, Roche-Chugai; research grants from CSL Behring, Johnson&Johnson, GSK, Roche-Chugai; outside the submitted work. ZA reports speaking and consultancy fees from GSK. ED reports speaking fees from GSK, Amgen, AstraZeneca; consultancy fees from GSK, AstraZeneca, Amgen; research grant from Roche; outside the submitted work.

Figures

Figure 1
Figure 1
Flow diagram of the study population. CKD, chronic kidney disease; IST, immunosuppressive therapy; SLE, systemic lupus erythematosus.
Figure 2
Figure 2
Survival analyses. (A) Survival without renal relapse. (B) Survival without severe SLE flare (online supplemental material). IST, immunosuppressive therapy; SLE, systemic lupus erythematosus.
See this image and copyright information in PMC

References

    1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413–24. 10.1681/ASN.V102413 - DOI - PubMed
    1. Arnaud L, Tektonidou MG. Long-Term outcomes in systemic lupus erythematosus: trends over time and major contributors. Rheumatology 2020;59:v29–38. 10.1093/rheumatology/keaa382 - DOI - PMC - PubMed
    1. Dörner T, Furie R. Novel paradigms in systemic lupus erythematosus. Lancet 2019;393:2344–58. 10.1016/S0140-6736(19)30546-X - DOI - PubMed
    1. Moroni G, Frontini G, Ponticelli C. When and how is it possible to stop therapy in patients with lupus nephritis? Clin J Am Soc Nephrol 2021. 10.2215/CJN.04830421 - DOI - PMC - PubMed
    1. Lightstone L, Doria A, Wilson H, et al. . Can we manage lupus nephritis without chronic corticosteroids administration? Autoimmun Rev 2018;17:4–10. 10.1016/j.autrev.2017.11.002 - DOI - PubMed

Publication types

Associated data